[Erythropoietin and hypertension].
Hypertension is one of the adverse effects associated with recombinant human erythropoietin (rHuEPO) therapy for anaemia in hemodialysed patients. The incidence of hypertension is reported to be 10-15%. The exact mechanism of rHuEPO-induced hypertension has not been fully elucidated, although in this paper several theories have been presented.
A
A
Azzadin
W
W
Buczko
D000740:Anemia / Q000188:drug therapy; D004921:Erythropoietin / Q000009:adverse effects*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin
Erytropoetyna a nadciśnienie.